MBX Biosciences, Inc.
Every calculator, already run for MBX
Open the full toolkit →You have the numbers on MBX. Get the argument.
A written report on which of these readings actually decide the outcome for MBX Biosciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
12 analysts covering MBXAnalyst Price Target Disagreement for MBX Biosciences, Inc.
Wall Street's bull case implies +96% from the current price; the bear case implies +13%. A 83% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for MBX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate,…
MBX — frequently asked
Is MBX a buy right now?
Wall Street's consensus rating on MBX Biosciences, Inc. is Strong Buy across 12 analysts, with a mean price target of $88.36 (+43% vs. the current $61.72). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is MBX's next earnings date?
MBX Biosciences, Inc. is next scheduled to report earnings around Nov 5, 2026. A full MBX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for MBX Biosciences, Inc.?
Analysts covering MBX Biosciences, Inc. (MBX) range from a bear-case target of $70.00 to a bull-case high of $121.00, with a mean consensus target of $88.36 across 11 analysts. The spread of $51.00 (83% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare MBX Biosciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For MBX Biosciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MBX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on MBX Biosciences, Inc., in minutes. 3 free reports included with every account — no credit card required.